|
1.
|
|
9 p, 754.3 KB |
The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients
/
Sastre, Lydia (Hospital Clínic i Provincial de Barcelona) ;
García, Raquel (Hospital Clínic i Provincial de Barcelona) ;
Gándara, Julián-Gonzalo (Hospital Clínic i Provincial de Barcelona) ;
Fernandez-Llama, Patricia (Institut d'Investigació Biomèdica Sant Pau) ;
Amor Fernández, Antonio J. (Hospital Clínic i Provincial de Barcelona) ;
Sierra, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Escudé, Laia (Hospital Clínic i Provincial de Barcelona) ;
Ruiz, Pablo (Hospital Clínic i Provincial de Barcelona) ;
Colmenero, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Ortega, Emilio (Hospital Clínic i Provincial de Barcelona) ;
Navasa, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Crespo, Gonzalo (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Long-term cardiovascular (CV) events are a frequent cause of death and disability after liver transplant (LT). Although a more in-depth, risk-adapted control of CV risk factors may result in improved post-LT CV outcomes, an accurate stratification of the CV risk of LT recipients to better implement preventive strategies is lacking. [...]
2021 -  10.1097/TXD.0000000000001272
Transplantation Direct, Vol. 8 Núm. 1 (23 2021) , p. E1272
|
|
|
2.
|
|
10 p, 203.8 KB |
Cancer Incidence in Heart Transplant Recipients with Previous Neoplasia History
/
Delgado-Jiménez, Juan Francisco (Hospital 12 de Octubre (Madrid)) ;
Alonso-Pulpón, L. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Mirabet Pérez, Sonia (Institut d'Investigació Biomèdica Sant Pau) ;
Almenar Bonet, Luis (Hospital Universitari i Politècnic La Fe (València)) ;
Pérez-Villa, Félix (Hospital Clínic i Provincial de Barcelona) ;
González-Vílchez, Francisco (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Palomo, J. (Hospital General Universitario Gregorio Marañón) ;
Blasco, T. (Hospital Universitario Miguel Servet (Saragossa)) ;
Dolores García-Cosio, M. (Hospital 12 de Octubre (Madrid)) ;
González-Costello, J. (Hospital Universitari de Bellvitge) ;
de la Fuente Galán, Luis (Hospital Clínico Universitario de Valladolid) ;
Rábago Juan-Aracil, Gregorio (Clínica Universidad de Navarra) ;
Lage, E. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Pascual-Figal, Domingo Andrés (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Díaz-Molina, Beatriz (Hospital Universitario Central de Asturias) ;
Arizón, J. M (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Muñiz, Javier (Instituto Universitario de Ciencias de la Salud Instituto de Investigacion Biomedica de A Coruna. Universidade da Coruña) ;
Crespo-Leiro, Maria Generosa (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
Neoplasm history increases morbidity and mortality after solid organ transplantation and has disqualified patients from transplantation. Studies are needed to identify factors to be considered when deciding on the suitability of a patient with previous tumor for heart transplantation. [...]
2016 - 10.1111/ajt.13637
American Journal of Transplantation, Vol. 16 Núm. 5 (january 2016) , p. 1569-1578
|
|
|
3.
|
|
10 p, 903.6 KB |
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Medical College of Wisconsin) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ;
Yoon, Sung-Soo (Seoul National University Hospital) ;
Maeda, Yoshinobu (Okayama University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Kato, Takayrasu (Department of Hematology. University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ;
Hasabou, Nahla (Astellas Pharma US. Inc.) ;
Nuthethi, Rishita (Astellas Pharma US. Inc.) ;
Tiu, Ramon (Astellas Pharma US. Inc.) ;
Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 - 10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10
|
|
|
4.
|
|
13 p, 1.2 MB |
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy : A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research
/
Schoettler, M.L. (Children's Healthcare of Atlanta) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Byung-Sik (The Catholic University of Korea) ;
Dandoy, Christopher E. (Cincinnati Children's Hospital Medical Center) ;
Ho, Vincent Trien Vinh (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Jodele, Sonata (Cincinnati Children's Hospital Medical Center) ;
Moissev, I. (Pavlov First Saint Petersburg State Medical University) ;
Sańchez Ortega, Isabel (European Society for Bone Marrow Transplant) ;
Srivastava, Alok (Christian Medical College Vellore) ;
Atsuta, Yoshiko (Aichi Medical University) ;
Carpenter, Paul A. (Seattle Children's Hospital) ;
Koreth, John (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Kröger, Nicolaus M. (Ohio State. University) ;
Ljungman, Per (Karolinska Institutet (Estocolm, Suècia)) ;
Page, Kristin M. (Medical College of Wisconsin) ;
Popat, Uday R. (The University of Texas MD Anderson Cancer Center) ;
Shaw, Bronwen E. (Medical College of Wisconsin) ;
Sureda Balari, Anna Maria (Institut Catala d'Oncologia-Hospital Duran i Reynals) ;
Soiffer, Robert J. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Vasu, Sumithira V. (Ohio State. University)
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. [...]
2023 - 10.1016/j.jtct.2022.11.015
Transplantation and Cellular Therapy, Vol. 29 Núm. 3 (march 2023) , p. 151-163
|
|
|
5.
|
|
8 p, 894.2 KB |
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
/
Kekre, N. (The Ottawa Hospital) ;
Marquez-Malaver, Francisco J. (Instituto de Biomedicina de Sevilla) ;
Cabrero, Monica (Instituto Biosanitario de Salamanca (IBSAL)) ;
Piñana, J. (Hospital Clínic Universitari (València)) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Soiffer, Robert J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Caballero, Dolores (Instituto Biosanitario de Salamanca (IBSAL)) ;
Terol, M.J. (Hospital Clínic Universitari (València)) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Antin, Joseph H. (Harvard Medical School) ;
Lopez-Corral, L. (Instituto Biosanitario de Salamanca (IBSAL)) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
Armand, Philippe (Harvard Medical School) ;
Pérez-Simon, Jose A. (Instituto de Biomedicina de Sevilla) ;
Universitat Autònoma de Barcelona
There is at present little data to guide the choice of conditioning for patients with lymphoma undergoing reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). In this study, we compared the outcomes of patients undergoing RIC SCT who received fludarabine and melphalan (FluMel), the standard RIC regimen used by the Spanish Group of Transplantation, and fludarabine and busulfan (FluBu), the standard RIC regimen used by the Dana-Farber Cancer Institute/Brigham and Women's Hospital. [...]
2016 - 10.1016/j.bbmt.2016.07.006
Biology of blood and marrow transplantation, Vol. 22 Núm. 10 (january 2016) , p. 1808-1815
|
|
|
6.
|
|
5 p, 178.9 KB |
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation : A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico
/
Orti, Guillermo (Grupo Español de Trasplante Hematopoyetico) ;
Sanz, Jaime (Grupo Español de Trasplante Hematopoyetico) ;
Bermudez, Arancha (Grupo Español de Trasplante Hematopoyetico) ;
Caballero, Dolores (Grupo Español de Trasplante Hematopoyetico) ;
Martinez, Carmen (Grupo Español de Trasplante Hematopoyetico) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Cabrera Marin, José R. (Grupo Español de Trasplante Hematopoyetico) ;
Espigado, Ildefonso (Grupo Español de Trasplante Hematopoyetico) ;
Solano, Carlos (Grupo Español de Trasplante Hematopoyetico) ;
Ferrà, Christelle (Grupo Español de Trasplante Hematopoyetico) ;
García-Noblejas, Ana (Grupo Español de Trasplante Hematopoyetico) ;
Jimenez, Santiago (Grupo Español de Trasplante Hematopoyetico) ;
Sampol, Antonia (Grupo Español de Trasplante Hematopoyetico) ;
Yañez, Lucrecia (Grupo Español de Trasplante Hematopoyetico) ;
García-Gutiérrez, Valentin (Grupo Español de Trasplante Hematopoyetico) ;
Pascual, Maria Jesus (Grupo Español de Trasplante Hematopoyetico) ;
Jurado, Manuel (Grupo Español de Trasplante Hematopoyetico) ;
Moraleda, José M. (Grupo Español de Trasplante Hematopoyetico) ;
Valcarcel, David (Grupo Español de Trasplante Hematopoyetico) ;
Sanz, Miguel A. (Grupo Español de Trasplante Hematopoyetico) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Duarte, Rafael F. (Grupo Español de Trasplante Hematopoyetico) ;
Universitat Autònoma de Barcelona
Allogeneic stem cell transplantation (allo-HCT) represents the most effective immunotherapy for acute myeloid leukemia (AML) and myeloid malignancies. However, disease relapse remains the most common cause of treatment failure. [...]
2016 - 10.1016/j.bbmt.2015.11.012
Biology of blood and marrow transplantation, Vol. 22 Núm. 3 (january 2016) , p. 584-588
|
|
|
7.
|
|
7 p, 480.5 KB |
Cord Blood Units with High CD3+ Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation
/
Castillo, N. (Banc de Sang i Teixits) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Ferrá, Christelle (Institut Català d'Oncologia) ;
Canals, Carme (Banc de Sang i Teixits) ;
Elorza, Izaskun (Hospital Universitari Vall d'Hebron) ;
Olivé, Teresa (Hospital Universitari Vall d'Hebron) ;
Badell Serra, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Querol, Sergio (Banc de Sang i Teixits) ;
Universitat Autònoma de Barcelona
Although high absolute lymphocyte count (ALC) early after transplantation is a simple surrogate for immune reconstitution, few studies to date have established the predictive factors for ALC after umbilical cord blood transplantation (UCBT). [...]
2016 - 10.1016/j.bbmt.2016.03.009
Biology of blood and marrow transplantation, Vol. 22 Núm. 6 (january 2016) , p. 1073-1079
|
|
|
8.
|
|
34 p, 950.5 KB |
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
/
Pasquini, Marcelo (Medical College of Wisconsin) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Medeiros, Bruno (Stanford University School of Medicine) ;
Armand, Philippe (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hu, Zhen-Huan (Medical College of Wisconsin) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Aljurf, Mahmoud D. (King Faisal Specialist Hospital Center and Research) ;
Akpek, Görgün (Banner MD Anderson Cancer Center) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell S. (New York Medical College) ;
Cerny, Jan (UMass Memorial Medical Center) ;
Copelan, Edward A. (Carolinas HealthCare System) ;
Deol, Abhinav (Wayne State University) ;
Freytes, César O. (University of Texas Health Science Center San Antonio) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Medical Center) ;
George, Biju (Christian Medical College) ;
Gupta, Vikas (University Health Network) ;
Hale, Gregory A. (All Children's Hospital) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Klumpp, Thomas R. (Thomas Jefferson University Hospital) ;
Lazarus, Hillard M. (University Hospitals Case Medical Center) ;
Luger, Selina M. (University of Pennsylvania Medical Center) ;
Liesveld, Jane L. (University of Rochester Medical Center) ;
Litzow, Mark Robert (Mayo Clinic) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Norkin, Maxim (University of Florida College of Medicine) ;
Olsson, Richard F. (Uppsala University) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Pawarode, Attaphol (University of Michigan) ;
Pulsipher, Michael A. (University of Southern California Keck School of Medicine) ;
Ramanathan, Muthalagu (UMass Memorial Medical Center) ;
Reshef, Ran (University of Pennsylvania Medical Center) ;
Saad, Ayman A. (University of Alabama at Birmingham) ;
Saber, Wael (Medical College of Wisconsin) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Ringdén, Olle (Centre for Allogeneic Stem Cell Transplantation) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center) ;
Uy, Geoffrey L. (Washington University School of Medicine) ;
Wood, William A. (University of North Carolina) ;
Wirk, Baldeep (Seattle Cancer Care Alliance) ;
Pérez, Waleska S. (Medical College of Wisconsin) ;
Batiwalla, Minoo (National Heart Lung and Blood Institute - National Institutes of Health) ;
Weisdorf, Daniel J. (University of Minnesota Medical Center) ;
Universitat Autònoma de Barcelona
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. [...]
2016 - 10.1016/j.bbmt.2015.08.024
Biology of blood and marrow transplantation, Vol. 22 Núm. 2 (january 2016) , p. 248-257
|
|
|
9.
|
|
3 p, 444.0 KB |
Prevention of veno-occlusive disease/sinusoidal obstruction syndrome : a never-ending story and no easy answer
/
Corbacioglu, Selim (University of Regensburg) ;
Grupp, S.A. (The Children's Hospital of Philadelphia) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Duarte, R. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Pagliuca, A. (King's College Hospital and Anthony Nolan Research Institute) ;
Ruutu, T. (Helsinki University Hospital) ;
Mahadeo, K. (Duke University Children's Hospital) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
2023 - 10.1038/s41409-023-02007-2
Bone marrow transplantation, Vol. 58 Núm. 8 (august 2023) , p. 839-841
|
|
|
10.
|
|
7 p, 784.4 KB |
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma : A GELTAMO Trial
/
Cabrero, Monica (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Martín García-Sancho, Alejandro (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Gayoso, Jorge (Hospital General Universitario Gregorio Marañón) ;
Jarque, Isidro (Hospital Universitari i Politècnic La Fe (València)) ;
López, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ;
Grande García, Carlos (Hospital 12 de Octubre (Madrid)) ;
Heras, Inmaculada (Hospital Morales Messeguer) ;
Arranz, Reyes (Hospital Universitario de la Princesa (Madrid)) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
Perez-Lopez, Estefenia (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
López-Godino, Oriana (Hospital Morales Messeguer) ;
Conde, Eulogio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Caballero, Dolores (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Universitat Autònoma de Barcelona
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). [...]
2017 - 10.1016/j.bbmt.2016.10.003
Biology of blood and marrow transplantation, Vol. 23 Núm. 1 (january 2017) , p. 53-59
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
